T-cell recognition of a prostate specific antigen is not sufficient to induce prostate tissue destruction

Prostate

Volumn 66, Issue 6, 2006, Pages 578-590

  Lees, Jason R ^a,b   Charbonneau, Bridget ^a   Hayball, John D ^c   Diener, Kerrilyn ^c   Brown, Michael ^c   Matusik, Robert ^d   Cohen, Michael B ^b   Ratliff, Timothy L ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c University of Adelaide   (Australia)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

Cytotoxic T lymphocytes; Prostate inflammation; Tissue specific antigen; Tolerance

Indexed keywords

OVALBUMIN; PROSTATE SPECIFIC ANTIGEN; T LYMPHOCYTE RECEPTOR;

ADOLESCENT; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STRAIN; CELL STRAIN OT 1; CELL TRANSPORT; CELLULAR DISTRIBUTION; CONTROLLED STUDY; INFLAMMATORY CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE INJURY; PROSTATITIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TISSUE INJURY; TRANSGENIC MOUSE;

ADOPTIVE TRANSFER; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DNA PRIMERS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OVALBUMIN; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYMUS GLAND; URINARY BLADDER;

EID: 33645932608     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20307     Document Type: Article

References (31)

1. Alexander RB, Brady F, Poruiiah S. Autoimmune prostatitis: Evidence of T-cell reactivity with normal prostatic proteins. Urology 1997;50(6):893-899.
2. Maccioni M, Rivero VE, Riera CM. Prostatein (or rat prostatic steroid binding protein) is a major autoantigen in experimental autoimmune prostatitis. Clin Exp Immunol 1998;112(2):159-165.
3. Liu KJ, Chatta GS, Twardzik DR, Vedvick TS, True LD, Spies AG, Cheever MA. Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis: Implications for prostate cancer therapy. J Immunol 1997;159(1):472-480.
4. Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: Implications for immunotherapy of prostate cancer. J Immunol 1997;159(7):3113-3117.
5. Rivero V, Carnaud C, Riera CM. Prostatein or steroid binding protein (PSBP) induces experimental autoimmune prostatitis (EAP) in NOD mice. Clin Immunol 2002;105(2):176-184.
6. Plautz GE, Mukai S, Cohen PA, Shu S. Cross-presentation of tumor antigens to effector T-cells is sufficient to mediate effective immunotherapy of established intracranial tumors. J Immunol 2000;165(7):3656-3662.
7. Kobayashi H, Omiya R, Sodey B, Yanai M, Oikawa K, Sato K, Kimura S, Senju S, Nishimura Y, Tateno M, Celis E. Identification of naturally processed helper T-cell epitopes from prostate-specific membrane antigen using peptide-based in vitro stimulation. Clin Cancer Res 2003;9(14):5386-5393.
8. Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, Engleman EG. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 2001;167(12):7150-7156.
9. Zheng X, Gao JX, Zhang H, Geiger TL, Liu Y, Zheng P. Clonal deletion of simian virus 40 large T antigen-specific T-cells in the transgenic adenocarcinoma of mouse prostate mice: An important role for clonal deletion in shaping the repertoire of T-cells specific for antigens overexpressed in solid tumors. J Immunol 2002;169(9):4761-4769.
10. Masumori N, Thomas TZ, Chaurand P, Case T, Paul M, Kasper S, Caprioli RM, Tsukamoto T, Shappell SB, Matusik RJ. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res 2001;61(5):2239-2249.
11. Zhang J, Gao N, Kasper S, Reid K, Nelson C, Matusik RJ. An androgen-dependent upstream enhancer is essential for high levels of probasin gene expression. Endocrinology 2004;145(1):134-148.
12. Zhang J, Thomas TZ, Kasper S, Matusik RJ. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 2000;141(12):4698-4710.
13. Andriani F, Nan B, Yu J, Li X, Weigel NL, McPhaul MJ, Kasper S, Kagawa S, Fang B, Matusik RJ, Denner L, Marcelli M. Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells. J Natl Cancer Inst 2001;93(17):1314-1324.
14. Kurts C, Heath WR, Carbone FR, Allison J, Miller JF, Kosaka H. Constitutive class I-restricted exogenous presentation of self-antigens in vivo. J Exp Med 1996;184(3):923-930.
15. Kurts C, Carbone FR, Barnden M, Blanas E, Allison J, Heath WR, Miller JF. CD4+ T-ceII help impairs CD8+ T-cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. J Exp Med 1997;186(12):2057-2062.
16. Buhlmann JE, Gonzalez M, Ginther B, Panoskaltsis-Mortari A, Blazar BR, Greiner DL, Rossini AA, Flavell R, Noelle RJ. Cutting edge: Sustained expansion of CD8+ T-cells requires CD154 expression by Th cells in acute graft versus host disease. J Immunol 1999;162(8):4373-4376.
17. Bostwick DG, de la Roza G, Dundore P, Corica FA, Iczkowski KA. Intraepithelial and stromal lymphocytes in the normal human prostate. Prostate 2003;55(3):187-193.
18. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, Ellis TM, Wojcik EM, Yang D, Flanigan RC, Waters WB, Kast WM, Kwon ED. T-cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA 2001;98(25):14565-14570.
19. Granziero L, Krajewski S, Farness P, Yuan L, Courtney MK, Jackson MR, Peterson PA, Vitiello A. Adoptive immunotherapy prevents prostate cancer in a transgenic animal model. Eur J Immunol 1999;29(4):1127-1138.
20. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, AIlison JP. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000;60(9):2444-2448.
21. Sakaguchi S, Takahashi T, Yamazaki S, Kuniyasu Y, Itoh M, Sakaguchi N, Shimizu J. Immunologic self tolerance maintained by T-cell-mediated control of self-reactive T-cells: Implications for autoimmunity and tumor immunity. Microbes Infect 2001;3(11):911-918.
22. Adler AJ, Marsh DW, Yochum GS, Guzzo JL, Nigam A, Nelson WG, Pardoll DM. CD4+ T-cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J Exp Med 1998;187(10):1555-1564.
23. Zhang S, Gu J, Yang NS, Kao C, Gardner TA, Eble JN, Cheng L. Relative promoter strengths in four human prostate cancer cell lines evaluated by particle bombardment-mediated gene transfer. Prostate 2002;51(4):286-292.
24. Wu X, Wu J, Huang J, Powell WC, Zhang J, Matusik RJ, Sangiorgi FO, Maxson RE, Sucov HM, Roy-Burman P. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 2001;101(1-2):61-69.
25. Kurts C, Kosaka H, Carbone FR, Miller JF, Heath WR. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T-cells. J Exp Med 1997;186(2): 239-245.
26. Morgan DJ, Kreuwel HT, Sherman LA. Antigen concentration and precursor frequency determine the rate of CD8+ T-cell tolerance to peripherally expressed antigens. J Immunol 1999;163(2):723-727.
27. Morgan DJ, Liblau R, Scott B, Fleck S, McDevitt HO, Sarvetnick N, Lo D, Sherman LA. CD8(+) T-cell-mediated spontaneous diabetes in neonatal mice. J Immunol 1996;157(3):978-983.
28. Kreuwel HT, Sherman LA. Defects in deletional tolerance of CD8+ T-cells in autoimmune diabetes. Curr Dir Autoimmun 2001;4:123-143.
29. Kurts C, Klebba I, Davey GM, Koch KM, Miller JF, Heath WR, Floege J. Kidney protection against autoreactive CD8(+) T-cells distinct from immunoprivilege and Sequestration. Kidney Int 2001;60(2):664-671.
30. Limmer A, Sacher T, AIferink J, Kretschmar M, Schonrich G, Nichterlein T, Arnold B, Hammerling GJ. Failure to induce organ-specific autoimmunity by breaking of tolerance: Importance of the microenvironment. Eur J Immunol 1998;28(8):2395-2406.
31. Meidenbauer N, Harris DT, Spitler LE, Whiteside TL. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 2000;43(2):88-100.